Histogenics Corp., a regenerative medicine company based in Waltham, announced Tuesday the completion of a $49 million round of financing.
The syndicate was led by Sofinnova Ventures with participation from additional new investors Split Rock Partners, BioMed Ventures, and FinTech GIMV Fund L.P. Existing investors ProChon Holdings BV, Altima Partners, Foundation Medical Partners, Inflection Point Capital, and Boston Millennia Partners also participated in the financing, the company said in a press release.
The company said it plans to use the proceeds to complete the ongoing Phase 3 clinical program of its lead product candidate --- NeoCart.
According to Histogenics, NeoCart is an autologous neocartilage tissue implant that utilizes a patient’s own cells to regenerate cartilage in patients suffering from cartilage lesions in the knee.